N-(2-[(11)C]methoxybenzyl)-N-(4-phenoxy-3-pyridinyl)acetamide | 1005325-43-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-(2-[(11)C]methoxybenzyl)-N-(4-phenoxy-3-pyridinyl)acetamide
• 英文别名: [¹¹C]PBR28；[11C]PBR28；Carbon C 11 PBR-28；N-[(2-(111C)methoxyphenyl)methyl]-N-(4-phenoxypyridin-3-yl)acetamide
• CAS: 1005325-43-8
• 化学式: C₂₁H₂₀N₂O₃
• 分子量: 347.39
• InChiKey: DHZBNHMEIOBPAE-JVVVGQRLSA-N

物化性质

• 密度：
  1.203±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-(2-hydroxybenzyl)-N-(4-phenoxypyridin-3-yl)acetamide 生成 N-(2-[(11)C]methoxybenzyl)-N-(4-phenoxy-3-pyridinyl)acetamide
  参考文献：
  名称：

  J. Med. Chem. 2008, 51, 17-30

  摘要：

  DOI：

文献信息

• Highlighting the versatility of the Tracerlab synthesis modules. Part 2: fully automated production of [11C]-labeled radiopharmaceuticals using a Tracerlab FXC-Pro
  作者：Xia Shao、Raphaël Hoareau、Adam C. Runkle、Louis J. M. Tluczek、Brian G. Hockley、Bradford D. Henderson、Peter J. H. Scott

  DOI：10.1002/jlcr.1937

  日期：2011.12

  Herein, we continue our series of articles showcasing the versatility of the Tracerlab FX synthesis modules by presenting straightforward, fully automated methods for preparing a range of carbon‐11 labeled radiopharmaceuticals using a Tracerlab FXC‐Pro. Strategies for production of [11C]acetate, [11C]carfentanil, [11C]choline, [11C]3‐amino‐4‐[2‐[(di(methyl)amino)methyl]phenyl]sulfanylbenzonitrile ([11C]DASB)

  放射化学领域正在朝着自动合成模块的专用化方向发展，以生产临床放射药物剂量。这样的举动不仅具有许多优势，而且还给放射化学工作者带来了重新配置合成模块的挑战，以生产需要非常规放射化学同时又要保持全自动的放射性药物。在此，我们将继续介绍一系列文章，展示通过使用Tracerlab FX C-Pro制备一系列碳11标记的放射性药物的直接，全自动方法，来展示Tracerlab FX合成模块的多功能性。产生[ 11 C]乙酸盐，[ 11 C]芬太尼，[ 11 C]胆碱，[ 11C] 3-氨基-4- [2-[（（（（二（甲基）氨基）甲基]苯基]硫烷基苄腈（[ 11 C] DASB），（+）-[ 11 C]二氢萜烯嗪（[ 11 C] DTBZ） ，[ 11 C]氟马西尼（[ 11 C] FMZ），间羟基麻黄碱（[ 11 C] HED），[ 11 C]蛋氨酸，[ 11 C] PBR28，[ 11 C]匹兹堡化合物B（[
• DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT
  申请人：Lehmann Lutz

  公开号：US20110200535A1

  公开（公告）日：2011-08-18

  This invention relates to novel compounds suitable for labelling or already labelled by 18 F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for therapy and diagnostic imaging by positron emission tomography (PET).

  本发明涉及新的化合物，适用于标记或已被18F标记，制备这种化合物的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒，以及这种化合物、组合物或试剂盒在正电子发射断层扫描（PET）的治疗和诊断成像中的应用。
• ARYLOXYANILIDE DERIVATIVES
  申请人：Wadsworth Harry John

  公开号：US20120003154A1

  公开（公告）日：2012-01-05

  The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.

  本发明提供了一种新型放射性标记的芳氧基脯氨酸衍生物，适用于体内成像。与已知的芳氧基脯氨酸衍生物体内成像剂相比，本发明的体内成像剂具有更好的体内成像性能。本发明的体内成像剂在给予受试者后，表现出良好的选择性结合外周苯二氮平受体（PBR），结合良好的脑吸收和体内动力学。
• IN VIVO IMAGING METHOD FOR CANCER
  申请人：Jones Paul Alexander

  公开号：US20130183240A1

  公开（公告）日：2013-07-18

  The present invention provides a method useful in the diagnosis and monitoring of cancer wherein there is an abnormal expression of PBR. The method of the invention is particularly useful in evaluating the severity of the cancer, e.g. PBR expression correlates with cell proliferation rates, metastatic potential, tumour aggressiveness, malignancy progression. The method of the invention can therefore be applied in the determination of likely disease progression and in making an associated prognosis. Furthermore, the method of the invention can find use in determining the likely success of certain therapeutic approaches, or in the evaluation of the efficacy of certain proposed new treatments.

  本发明提供了一种在癌症诊断和监测中有用的方法，其中PBR的表达异常。本发明的方法特别适用于评估癌症的严重程度，例如PBR的表达与细胞增殖率、转移潜力、肿瘤侵袭性、恶性进展相关。因此，本发明的方法可用于确定可能的疾病进展，并作出相关预后。此外，本发明的方法可用于确定某些治疗方法的可能成功率，或评估某些拟议新治疗方法的疗效。
• Synthesis and Evaluation in Monkey of Two Sensitive ¹¹C-Labeled Aryloxyanilide Ligands for Imaging Brain Peripheral Benzodiazepine Receptors In Vivo
  作者：Emmanuelle Briard、Sami S. Zoghbi、Masao Imaizumi、Jonathan P. Gourley、H. Umesha Shetty、Jinsoo Hong、Vanessa Cropley、Masahiro Fujita、Robert B. Innis、Victor W. Pike

  DOI：10.1021/jm0707370

  日期：2008.1.1

  We sought to develop C-11-labeled ligands for sensitive imaging of brain peripheral benzodiazepine receptors (PBR) in vivo. Two aryloxyanilides with high affinity for PBR were identified and synthesized, namely, N-acetyl-N-(2-methoxycarbonylbenzyl)-2-phenoxyaniline (3, PBR01) and N-(2-methoxybenzyI)-N-(4-phenoxypyridin-3-yl)acetamide (10, PBR28). 3 was hydrolyzed to 4, which was esterified with [C-11]iodomethane to provide [C-11]3. The O-desmethyl analogue of 10 was converted into [C-11]10 with [C-11]iodomethane. [C-11]3 and [C-11]10 were each injected into monkey to assess their brain kinetics with positron emission tomography (PET). After administration of either radioligand there was moderately high brain uptake of radioactivity. Receptor blocking and displacement experiments showed that a high proportion of this radioactivity was bound specifically to PBR. In monkey and rat, 3 and 10 were rapidly metabolized by ester hydrolysis and N-debenzylation, respectively, each to a single polar radiometabolite. [C-11]3 and [C-11]10 are effective for imaging PBR in monkey brain. [C-11]10 especially warrants further evaluation in human subjects.